BRAF and colorectal carcinoma: To test the hypothesis that SRC is a druggable vulnerability in BRAF inhibitor-resistant BRAFV600E CRC, we first assessed the sensitivity of WiDr cells to two-drug combinations including a BRAF inhibitor and another kinase inhibitor, chosen on the basis of the kinase signatures in Fig. 1b.